GET DAILY SIGNALSPrivia Health (PRVA) Delivers +13.2% Revenue Growth Despite Adjusted EPS Miss
Key Takeaways
- Privia Health reported third-quarter 2026 revenue of $656.96 million, up 13.2% year over year and roughly 7.5% above the consensus estimate of $611.3 million.
- Adjusted earnings per share (EPS) came in at $0.21, below the consensus estimate of $0.24, marking an 11.8% miss despite the strong top line.
- Adjusted EBITDA rose 6.3% to $40.59 million, modestly ahead of the $39.02 million consensus.
- Management raised full-year 2026 guidance above the initial high end for every key financial metric, the company's third straight upward revision this year.
- Implemented providers grew 12.2% to 5,893, and attributed lives climbed 19.2% to 1.676 million, signaling continued expansion of the provider network.
- Shares slipped roughly 2% after the release, reflecting investor concerns about slower profit growth and softer cash conversion.
Understanding Privia Health's Business and Recent Performance
Privia Health Group, Inc. operates a physician enablement platform that helps independent medical practices manage value-based care, shared savings, and administrative functions. Its quarterly results are closely watched because they reveal both the pace of provider adoption and the profitability of its care delivery model. Heading into the third quarter of 2026, Privia had delivered consecutive beat-and-raise quarters, and investors were focused on whether revenue growth could translate into sustained margin expansion. The results matter beyond PRVA itself, offering a window into broader trends in value-based care, Medicare shared savings, and healthcare technology spending at a time when the sector faces shifting reimbursement dynamics. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Breaking Down the Q3 2026 Numbers
For the three months ended September 30, 2026, Privia Health reported revenue of $656.96 million, an increase of 13.2% from $580.42 million in the prior-year period and ahead of the $611.3 million consensus estimate. The company's top-line growth reflected continued provider network expansion, with implemented providers rising 12.2% to 5,893 and attributed lives increasing 19.2% to 1.676 million.
On the bottom line, adjusted EPS was $0.21, below the consensus estimate of $0.24 and down from $0.29 in the same quarter a year earlier. GAAP diluted EPS was $0.10, up from $0.05 in the prior-year period, while net income attributable to Privia Health reached $13.49 million. Adjusted EBITDA rose 6.3% to $40.59 million, slightly above the $39.02 million consensus, though the growth rate decelerated sharply from the company's year-to-date pace.
Management raised full-year 2026 guidance above the initial high end across key metrics, pointing to a revenue midpoint of approximately $2.53 billion and an adjusted EBITDA midpoint near $155.5 million. Shared savings revenue, however, declined to $68.8 million from $80.0 million a year earlier, and operating cash flow turned negative through nine months as receivables grew.
How the Market Responded
Privia Health shares slipped approximately 2% to around $21.95 immediately after the release, suggesting the market focused on the earnings miss and slowing profit growth rather than the revenue beat and raised guidance. The divergence between strong top-line momentum and a weaker-than-expected adjusted EPS figure captured the core tension in the results. While revenue growth of 13.2% remained healthy, adjusted EBITDA growth of 6.3% lagged the company's nine-month pace of roughly 22%, and softer cash conversion added another layer of caution. Investor sentiment appeared divided between confidence in the company's expanding provider network and concerns about whether that growth can translate into faster, more predictable profitability.
What to Watch Going Forward
Looking ahead, investors will be watching whether Privia Health can convert its expanding provider base and attributed lives into accelerating margin expansion. Management's raised full-year guidance implies meaningful improvement in the second half of 2026, but the deceleration in quarterly EBITDA growth suggests the path may not be linear.
One key factor to monitor is cash flow. Operating cash flow was negative through the first nine months of 2026, and management has modestly lowered its free cash flow conversion expectations. The timing of Medicare Shared Savings Program (MSSP) settlements, which are expected to be received in November, will be an important near-term catalyst for the balance sheet.
Investors should also track shared savings revenue, which declined year over year, and the company's capital deployment plans. Management has signaled growing appetite for acquisitions and, for the first time, a lower bar for share buybacks in the absence of deal activity. The planned addition of a Medicare ACO is expected to contribute to lives and EBITDA beginning in 2027. As Privia navigates a shifting value-based care landscape, its ability to sustain provider growth while improving profitability and cash generation will remain central to the investment narrative. From what I see, this is important because sustained execution here could support a more durable valuation multiple over time.
Using AI Tools in My Research Process
I often turn to Tickeron’s AI Screener when evaluating earnings reports like this one. It lets me quickly filter for similar healthcare names based on technical patterns, fundamentals, and performance metrics, which helps put PRVA’s results in broader context without spending hours on manual screening. The tool has become a regular part of how I refine watchlists around quarterly updates.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PRVA in upward trend: price rose above 50-day moving average on October 12, 2026
PRVA moved above its 50-day moving average on October 12, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 47 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 45 of 61 cases where PRVA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 74%.
The 10-day moving average for PRVA crossed bullishly above the 50-day moving average on October 15, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 78%.
Following a +5.26% 3-day Advance, the price is estimated to grow further. Considering data from situations where PRVA advanced for three days, in 197 of 274 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 136 of 211 cases where PRVA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 64%.
Bearish Trend Analysis
The 10-day RSI Indicator for PRVA moved out of overbought territory on October 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 22 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Momentum Indicator moved below the 0 level on October 29, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PRVA as a result. In 74 of 88 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 84%.
The Moving Average Convergence Divergence Histogram (MACD) for PRVA turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 37 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PRVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
PRVA broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating fairly steady price growth. PRVA’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 92 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.909) is normal, around the industry mean (4.886). PRVA's P/E Ratio (104.087) is considerably higher than the industry average of (13.782). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.133). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.127) is also within normal values, averaging (6.065).
The Tickeron PE Growth Rating for this company is 92 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 97 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PRVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry ServicestotheHealthIndustry
Advertisement